期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 148, 期 1, 页码 16-24出版社
WILEY
DOI: 10.1038/sj.bjp.0706709
关键词
arrhythmia; sodium channel; heart; persistent current; long QT syndrome
资金
- NHLBI NIH HHS [R01 HL056810, HL-56810-08] Funding Source: Medline
1 We studied the effects of ranolazine, an antianginal agent with promise as an antiarrhythmic drug, on wild-type (WT) and long QT syndrome variant 3 (LQT-3) mutant Na+ channels expressed in human embryonic kidney (HEK) 293 cells and knock-in mouse cardiomyocytes and used site-directed mutagenesis to probe the site of action of the drug. 2 We find preferential ranolazine block of sustained vs peak Na+ channel current for LQT-3 mutant (Delta KPQ and Y1795C) channels (IC50 = 15 vs 135 mu M) with similar results obtained in HEK 293 cells and knock-in myocytes. 3 Ranolazine block of both peak and sustained Na+ channel current is significantly reduced by mutation (F1760A) of a single residue previously shown to contribute critically to the binding site for local anesthetic (LA) molecules in the Na+ channel. 4 Ranolazine significantly decreases action potential duration (APD) at 50 and 90% repolarization by 23 +/- 5 and 27 +/- 3%, respectively, in Delta KPQ mouse ventricular myocytes but has little effect on APD of WT myocytes. 5 Computational modeling of human cardiac myocyte electrical activity that incorporates our voltage-clamp data predicts marked ranolazine-induced APD shortening in cells expressing LQT-3 mutant channels. 6 Our results demonstrate for the first time the utility of ranolazine as a blocker of sustained Na+ channel activity induced by inherited mutations that cause human disease and further, that these effects are very likely due to interactions of ranolazine with the receptor site for LA molecules in the sodium channel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据